Tableting—a Focus for Continuous Improvement - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Tableting—a Focus for Continuous Improvement

Pharmaceutical Technology Europe
Volume 26, Issue 8, pp. 26
PharmTech Europe 25th Anniversary
DSGpro/Getty Images;
Art direction: Dan Ward

Surveying the Landscape of Solid-Dosage Manufacturing

Experts take a look at the journey travelled thus far and where pharmaceutical manufacturing is heading over the next decade.

Current efforts to tackle the ongoing challenges in tablet manufacture are shaped by two features of the industrial landscape: quality by design (QbD) and continuous manufacturing. The quality of finished tablets is defined by critical quality attributes (CQAs) such as assay, weight, hardness and disintegration. However, ensuring these CQAs is made difficult by the number of steps involved in tablet production. Identifying analytical technologies that can be used to connect CQAs with the critical processing parameters (CPPs) for each individual step is a shared objective for the successful implementation of both QbD and continuous tablet manufacture.

Figure 1summarises the operations involved in continuous tablet manufacture, each of which has the potential to impact the CQAs of the tablet. This multi-step nature of tablet production means that there are many CPPs to assess and many process variables that directly affect the quality of the finished tablet. Indeed, estimates suggest the number of CPPs for a typical tableting process may be in excess of 100 (1).



Figure 1
Figure 1: Operations in continuous tablet manufacture. Figure 1 is courtesy of Freeman Technology

Pharmaceutical Technology Europe
25th Anniversary Issue

Quality by Design—a Fundamental Paradigm Shift in Pharmaceutical Manufacturing

Continuous Manufacturing—the Future of Pharmaceutical Manufacturing

Trends in Tablet Tooling

Advances in Film Coating

Polymers for Solubility Enhancement

Successful implementation of QbD in this environment relies on being able to measure properties of the in-process material at the exit of, for example, a granulator, which directly correlate with the CQAs of the tablet. Doing so enables the discrete development of each individual step, to build an efficient process, whether batch or continuous. Relevant process analytical technology (PAT) is crucial if this objective is to be achieved.

This PAT toolbox is likely to include techniques such as near infrared and particle sizing, but there is also additional value in measuring certain bulk properties of tableting blends and granules. Especially crucial is flowability, which as recent research has revealed, shows a direct correlation between the basic flowability energy of the granules exiting a wet granulation step and the hardness of tablets produced from them (2). Results such as these demonstrate the need to embrace a range of analytical techniques, whether in-line or at-line, to efficiently investigate and optimise each step of the tableting process. Selecting the most relevant analytical tools for tableting is paramount if the objectives of QbD are to be realised to their full potential.

1. Inna Ben-Anat, “QbD implementation in Generic Industry: Overview and Case Study,” presentation at IFPAC (Baltimore, Maryland, Jan. 2013).
2. J. Clayton and J. Yin, Pharm Technol 38 (6) 44-49 (2014).


Tim Freeman
Charles N. Kettle

About the Author
Tim Freeman, Freeman Technology


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here